Form 4: Organon Interim CEO Granted 131,233 Restricted Stock Units
Insider Transaction Report
Organon & Co.'s Interim CEO, Joseph T. Morrissey Jr., was granted 131,233 Restricted Stock Units, vesting over three years.
Summary
- Joseph T. Morrissey Jr., the Interim CEO of Organon & Co. (OGN), was granted 131,233 Restricted Stock Units (RSUs).
- Each RSU converts into one share of Organon & Co. common stock.
- The grant date for these RSUs was November 13, 2025, which was the third business day following the release of Organon's earnings for the quarter ended September 30, 2025.
- The RSUs will vest in three equal installments on November 13, 2026, November 13, 2027, and November 13, 2028.
- Following this transaction, Joseph T. Morrissey Jr. beneficially owns 131,233 derivative securities (RSUs).
Sentiment
Score: 7
Explanation: The grant of Restricted Stock Units to the Interim CEO is a positive step for aligning management's long-term interests with those of shareholders, indicating a commitment to the company's future performance. While not a direct financial performance indicator, it reflects standard, positive corporate governance in executive compensation.
Positives
- The grant of 131,233 Restricted Stock Units to the Interim CEO aligns management's long-term interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
- Equity compensation is a standard practice to incentivize executive retention and performance.
Negatives
- The vesting of these RSUs will result in future dilution for existing shareholders, although this is a common aspect of equity compensation plans.
Risks
- The value of the RSUs upon vesting is dependent on Organon & Co.'s stock price at the time of vesting, exposing the recipient to market risk.
- Future stock price declines could diminish the value of this compensation.
Future Outlook
The filing indicates a future vesting schedule for the granted Restricted Stock Units, with shares becoming exercisable in three equal installments on November 13, 2026, November 13, 2027, and November 13, 2028. This ties the Interim CEO's long-term compensation to the company's future performance.
Management Comments
- The grant of RSUs to Joseph T. Morrissey Jr. as Interim CEO reflects the company's compensation strategy to incentivize executive performance and retention.
Industry Context
The grant of Restricted Stock Units to an executive is a common form of equity compensation across various industries, particularly in publicly traded companies, to align management incentives with shareholder value creation.
Comparison to Industry Standards
- The use of Restricted Stock Units (RSUs) as a component of executive compensation is a widely adopted practice, comparable to compensation structures seen in other pharmaceutical and biotechnology companies.
- The multi-year vesting schedule is standard for long-term incentive plans, similar to those offered by peers like Pfizer, Merck, or Bristol Myers Squibb, ensuring sustained executive commitment.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Procedural Authorization | Joseph Morrissey executed a Power of Attorney on July 27, 2025, appointing Tarnetta V. Jones and Faye C. Brown as attorneys-in-fact to execute and file Forms 3, 4, and 5 on his behalf, and to manage his EDGAR account. This streamlines SEC filing compliance for the officer. | 07/27/2025 | Enhances efficiency and ensures timely compliance with Section 16(a) of the Securities Exchange Act of 1934 for insider transaction reporting. |
Stakeholder Impact
- Shareholders: The RSU grant aligns the Interim CEO's financial incentives with shareholder interests, potentially leading to decisions that enhance long-term stock value.
- Employees: Standard executive compensation practices can influence overall company morale and compensation structures.
Next Steps
- The granted Restricted Stock Units will vest in three equal installments on November 13, 2026, November 13, 2027, and November 13, 2028.
Key Dates
| Date | Description |
|---|---|
| 07/27/2025 | Date of execution of the Power of Attorney by Joseph Morrissey. |
| 11/10/2025 | Release of Organon's earnings for the quarter ended September 30, 2025. |
| 11/13/2025 | Transaction date for the grant of 131,233 Restricted Stock Units to Joseph T. Morrissey Jr. |
| 11/17/2025 | Signature date of the Form 4 filing by Faye C. Brown, as Attorney-in-Fact. |
| 11/13/2026 | First vesting date for one-third of the granted Restricted Stock Units. |
| 11/13/2027 | Second vesting date for one-third of the granted Restricted Stock Units. |
| 11/13/2028 | Third and final vesting date for one-third of the granted Restricted Stock Units. |
Keywords
Organon, OGN, Joseph T. Morrissey Jr., Restricted Stock Units, RSU, executive compensation, insider transaction, Form 4, equity grant
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.